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Abstract
Background: Results from HIV vaccine trials on potential volunteers will contribute to global efforts to develop an HIV 
vaccine. The purpose of this study among police officers in Dar es Salaam, Tanzania, was to explore the underlying 
reasons that induce people to enrol in an HIV vaccine trial.
Methods: We conducted discussions with eight focus groups, containing a total of 66 police officers. The information 
collected was analyzed using interpretive description.
Results: The results showed that participants were motivated to participate in the trial by altruism, and that the 
participants experienced some concerns about their participation. They stated that altruism in the fight against HIV 
infection was the main reason for enrolling in the trial. However, young participants were seriously concerned about a 
possible loss of close relationships if they enrolled in the HIV vaccine trial. Both men and women feared the effect of the 
trial on their reproductive biology, and they feared interference with pregnancy norms. They were unsure about risks 
such as the risks of acquiring HIV infection and of suffering physical harm, and they were unsure of the intentions of the 
researchers conducting the trial. Further, enrolling in the trial required medical examination, and this led some 
participants to fear that unknown diseases would be revealed. Other participants, however, saw an opportunity to 
obtain free health services.
Conclusions: We have shown that specific fears are important concerns when recruiting volunteers to an HIV vaccine 
trial. More knowledge is needed to determine participants' views and to ensure that they understand the conduct of 
the trial and the reasons it is being carried out.
Background
The search for an effective HIV vaccine through trials is
being actively pursued throughout the world. An exten-
sive body of literature is available that provides knowl-
edge about the factors that influence willingness to
participate in HIV vaccine trials. Most of these studies
are from high and middle-income countries. Some of
these studies have focused on populations at high risk [1-
4], while others have devoted attention to other groups in
the general population [5-8]. Few studies have looked into
willingness in low-income countries in Africa[9-13].
It is important to examine people's reasons for partici-
pating in clinical trials in different contexts, given that the
reasons not to enrol in HIV vaccine trials may differ.
Studies from high-income countries have identified a
number of such reasons, including a fear of vaccine-
induced HIV infection [4,14], a fear of negative side
effects of the vaccine [7,15,16], and worries about what
others will think or say about the participants [1]. In
South Africa, the major reasons for not participating in
HIV vaccine trials are fears that the vaccine may not be
safe [5] and a lack of information about vaccines [6]. In
* Correspondence: edith.tarimo@ki.se
1 Division of Global Health, Department of Public Health Sciences, Karolinska 
Institutet, Stockholm, Sweden
Full list of author information is available at the end of the articleBioMed Central
© 2010 Tarimo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Tarimo et al. BMC Public Health 2010, 10:292
http://www.biomedcentral.com/1471-2458/10/292
Page 2 of 11addition, community members in Africa may view vac-
cine research in various ways: they may suspect, for
example, that vaccines are a means of eliminating black
people by infecting them with AIDS [6]. Others may
agree to take part in a clinical trial while holding an opin-
ion that is not supported by the research protocol. In
Gambia, parents experienced a clinical trial as a route to
better and cheaper medical treatment for their children
[17]. Some studies have noted that there is an increasing
demand for basic HIV vaccine education to address cer-
tain vaccine trial concepts [10,11,18,19].
Tanzania has an HIV prevalence of 6.2% in the popula-
tion segment of 15-49 years old [20], and is one of the
low-income countries in Africa that is conducting HIV
vaccine trials [21]. A large HIV incidence study was con-
ducted among police officers, leading to a joint Phase I
and Phase II HIV vaccine trial. In a substudy of 329 police
officers, 127 (39%) were not willing to participate in a
Phase I and Phase II HIV vaccine trial [22]. This study
provided useful information, but did not examine in
depth the reasons that people refrained from enrolling in
the trial. Thus, the aim of the work presented here was to
examine how police officers reason around their decision
whether to volunteer or not in the HIV vaccine trial in
Tanzania. This study has used an interpretive description
(ID) approach [23]. ID can provide contextual under-
standing of the factors that influence the decision of a
police officer whether or not to take part in an HIV vac-
cine trial.
Methods
Study area and population
The study was conducted in eight out of 32 police sta-
tions according to the availability of study participants in
Dar es Salaam, Tanzania. Details of the study population
have been presented elsewhere [22,24]. This study was a
substudy of a larger Tanzania and Sweden (TANSWED)
HIV Program in Tanzania funded by Sida/SAREC. This
program includes studies of HIV incidence, studies of
laboratory reference values, and the analysis of willing-
ness to participate in HIV vaccine trials described here.
An extension of the program includes Phase I and II HIV
vaccine trials, as mentioned earlier. Police officers were
chosen for the study because they are well educated
(most of them have taken four years of secondary educa-
tion), come from an established organisation and are easy
to access. Previous studies had shown that they can make
independent informed decisions whether to take part in
HIV incidence studies and HIV vaccine trials that have
gained the support of higher police authorities [22,24].
Recruitment
Study participants were recruited based on information
from a previous study among police officers [22]. Of the
594 potential participants, 408 (68.6%) signed up for HIV
and AIDS education followed by an HIV vaccine trial
workshop. The field team (doctors, counsellors and
nurses) provided information about HIV and AIDS dur-
ing the workshop, described the HIV vaccine trial, and
described the potential benefits and risks of taking part.
Such benefits were: complete medical check up, free
medical services and referral to credited health centres if
a participant fell sick during the trial, follow-up visits, and
regular HIV testing. Risks included possible reactions
such as mild pain or tenderness, local redness, and vari-
ous systemic symptoms such as malaise, headache, mild
fever, and nausea [25]. The team clarified the inclusion
criteria, which included an age between 18 and 40 years
and an undertaking to use effective contraception
throughout the trial period.
Study design and sampling
This was an explorative study conducted among a sub-
group of the 408 police officers, a month after the work-
shop. The aim was to recruit groups of diverse
membership with respect to age, sex, rank, location of the
police station, marital status and whether the participant
had a caregiving role for a relative with AIDS. We
intended that such groups would create shared perspec-
tives. The first author (EAMT) characterized the 408 par-
ticipants according to the predetermined criteria, except
for whether the participant was a caregiver (those who
cared for a relative with AIDS in their families, see
below). EAMT, the fourth author (JM) and two field
assistants, a doctor and a nurse from the police health
department, visited the selected stations to explain the
objectives of the study and to ask for appointments. Par-
ticipants at these stations who met the inclusion criteria
for the substudy were recruited. The two field assistants
helped to recruit caregivers after the latter had been fully
informed about the focus, objectives, methodological
approaches and sensitivity of the study. The field assis-
tants occasionally used the snowball sampling strategy
[26] to come into contact with those who care for people
with AIDS in their families. The aim of recruiting persons
who cared for an AIDS patient was to obtain their views
about the topic. A total of 66 participants was recruited,
and formed a purposive sample [27] for this substudy
(Table 1).
Data collection procedures
We collected data between November 2006 and January
2007 using focus group discussions (FGDs). The mem-
berships of the FGD groups had been predetermined, but
the information collected was based on the principle of
'theoretical saturation' [28]. We therefore stopped enroll-
ing new groups when the information became repetitive
and it became clear that there was little to gain by includ-
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pared in English and then translated into Kiswahili before
use in the field. The guide comprised of general socio-
demographic background information and posed two
main research questions: (1) Can you tell me your views
about the problem of HIV and AIDS in the police force?
(2) What are the cultural norms, views and opinions
among police officers that may influence willingness to
volunteer for an HIV vaccine trial? The guide was refor-
mulated after the first two FGDs, to include emerging
perspectives such as the research questions: Who should
be told and why, if one decides to take part in the trial?,
and What opinions do you expect to see in other people?
We focus on the cultural norms, views and opinions
among police officers that may influence willingness to
take part in an HIV vaccine trial in the present report.
Findings from the first question will be presented else-
where. All FGDs were conducted at a location in the
police stations selected by the participants, and the num-
ber of participants varied between groups (Table 1). The
FGDs lasted between 25 and 71 minutes. The first author
(EAMT) moderated the FGDs and acted as a notetaker
interchangeably with JM. We have therefore applied tri-
angulation [27] of researchers (EAMT and JM) in data
collection in order to ensure consistency.
Ethical considerations
Participants were recruited after ethical approval had
been granted by the Muhimbili University of Health and
Allied Sciences' (MUHAS) Institutional Review Board,
and with the permission of the police authority. The first
author and moderator of FGDs reviewed the informed
consent form with potential participants and described
the principles of voluntary participation, anonymity and
the right to withdraw without any consequences for the
individual. The need to tape-record the discussion was
also explained. We employed multiple steps in obtaining
informed consent before the discussions took place (writ-
ten consent and oral consent, preceded by review of the
written consent with potential participants) to ensure
understanding and voluntary participation. All potential
participants gave their informed consent.
Data analysis
Analysis followed the interpretive description approach
informed by principles of thematic content analysis [23]
through an inductive design. The audio-taped FGDs were
transcribed verbatim and translated from Kiswahili to
English. EAMT listened to the tapes, and compared the
Kiswahili version with the English version to ensure accu-
racy. She repeatedly read all the transcripts to understand
the dataset, identify ideas, patterns and codes. The infor-
mation on the transcripts was inductively coded sepa-
rately by EAMT and the last author [AK], and then
discussed, in order to increase the validity and ensure the
quality of the analysis. There were no major differences.
This was followed by reading and comparing the codes
and developing categories and themes. The team then
discussed the preliminary findings with doctors, nurses,
counsellors and the two field assistants. The discussion
brought more insight into the interpretation. We have
therefore applied triangulation of researchers (EAMT
and AK) in data analysis in order to ensure consistency.
The interpretive process allowed the categories to be
organized into two subthemes and one main theme. The
categories, subthemes and the main theme were com-
pared with the FGD transcripts to ensure that interpre-
tive analysis reflects the content of the raw data. Finally,
all authors read the analysis and agreed on the categories
that had emerged. Quotations are given below to reflect
the voices of the participants.
Table 1: Participants in the focus group discussions (FGDs)
Group Inclusion Participants
1 Unmarried policewomen 30 years old or younger (Young policewomen) 7
2 Policewomen older than 30 years, of low rank (3 of these were married) (Older policewomen) 4
3 Low ranking policewomen of any age, 10 unmarried and 2 married (Low ranking policewomen) 12
4 Unmarried policemen 30 years old or younger (Young policemen) 12
5 High ranking policemen, all above 30 years old and married (High ranking policemen) 7
6 Low ranking policemen, all above 30 years old, half of them were married (Low ranking policemen) 6
7 Married and older policemen, mixed ranks (Married policemen) 12
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Participants
Of the 66 police officers, 35 were above 30 years old,
while the youngest participant was 19 years old. Most
participants were males and single (Table 1). The major-
ity had at least four years of secondary education.
Theme and subthemes
One main theme emerged that described the reason that
could contribute to police officers' decision to take part in
the HIV vaccine trial: 'Balancing collective responsibility
and individual concerns'. The theme includes subthemes
and categories (Table 2). The first subtheme, 'collectivism
in the HIV vaccine trial participation', highlights individ-
ual motivations, altruism, concerns for significant others
(parents, sexual partners, relatives, colleagues and
friends), reproduction and pregnancy norms, and a feel-
ing of responsibility for others in the efforts to save lives
from HIV infection. The second subtheme, 'uncertainty
of risks and opportunities', draws attention to the adverse
effects that may arise from participation in the trial and
the contrast between the perceived benefits and the
assurance of the researchers on the one hand, and mis-
trust on the other hand. The theme and its subthemes are
presented with some quotations to illustrate these inter-
actions.
Collectivism in the HIV vaccine trial participation
Individual motivations
Participants articulated several motives for participating
in the trial. These included: personal pride, and confi-
dence in a decision to participate in the trial. Some quota-
tions illustrate these motivations:
I will personally see myself as a hero (Young policeman
2, Group 4).
I will be confident and able to say 'I was among the
participants' [in the HIV vaccine trial] (Young police-
man 3, Group 4).
Participants expected to gain recognition that they felt
they deserved after taking part in an exercise that aimed
at saving the nation. They wanted to show off that they
had helped to make the HIV vaccine trial successful:
There is a saying: 'He who plays in his or her home
ground gets a reward...' I will be proud of myself, like
those who fought for independence, that I was among
those who fought for the vaccine (Low ranking police-
woman 1, Group 3).
Altruism
In addition, they referred to their obligation as police offi-
cers, that the role of protecting civilians could motivate
them to take part in the trial. So, they included, fulfilling
moral principles and self-sacrifice to save lives of millions
of people who are dying of HIV infection:
I think this [taking part in the trial] is part of motiva-
tion in my duty because if I get vaccinated and make it
successful, I will save the civilians whom I protect. And
to work as a police officer, there must be people to pro-
tect. No police force without people. I think this is one
of the moral principles that I should do (Low ranking
policewoman 10, Group 3).
Participants from other groups emphasised other posi-
tive results that would be experienced from the trial par-
ticipation:
When the results are good and successful, as a partici-
pant I will feel like the one who makes success in the
trial. I will be proud for making vaccine successful. I
Table 2: Theme, subthemes and categories
Main theme Balancing collective responsibility and individual concerns
Subthemes Collectivism in HIV vaccine trial participation Uncertainty of risks and opportunities
Categories Individual motivations Risks for HIV infection, myths and vaccine 
side effects
Altruism Time of knowing health status
Concerns for significant others (parents, sexual partners, 
relatives, colleagues and friends)
Medical check up: fear versus 
opportunities
Reproduction and pregnancy norms Researchers' assurance and mistrust
Responsibility for others
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successful (Low ranking policeman 2, Group 6).
The young policewomen based their altruistic reasons
for taking part in the trial on examples from religion.
They felt very responsible, and saw their participation as
a sacrifice for others:
I can imagine the vaccine like what Christians say:
Jesus was supposed to be crucified on the cross to save
lives of others, and that person [a volunteer] will be the
victory of saving the nation and the world (Young
policewoman 5, Group 1).
In contrast, an older policewoman argued that religious
issues and participation in the HIV vaccine trial are con-
flicting issues. She saw this conflict from the fact that the
trial rules required participants to postpone giving birth
to children, which is contrary to their religious beliefs.
She explained:
And we know that with religion, God said 'Give birth
to children, to multiply'. So when it comes to religion,
you [researchers] differ ... It is important (Older police-
woman 3, Group 2).
Overall, participants expressed their reason for taking
part is to help to make the trial successful.
Concern for significant others
As a counterweight to altruism, the fear of possible loss of
close relationships was mentioned as a reason for not vol-
unteering in the trial. The participants signalled that they
were confused by the reactions from their friends about
their decision to volunteer in the trial:
I volunteer for the vaccine. Where I go friends will start
telling me 'You were healthy and you have been given
AIDS'. If they say so, I will be affected psychologically
(Young policeman 4, Group 4).
The low ranking policewomen felt that colleagues
warned them against participation when they shared
their intent to take part in the trial. The colleagues
warned that they could get AIDS from the trial and would
thus be abandoned. Young policewomen also described
meeting similar reactions, and subsequently deciding not
to participate to avoid being abandoned:
Every time I told my colleague policewomen about this
[the HIV vaccine trial] they challenged me.... 'Go first
and get it [the vaccine] because you are HIV positive.'...
So I decided to quit... (Young policewoman 2, Group 1).
Other participants in the group agreed and supported
this discussion through gestures and body language.
Those living with their parents or spouses, and those
who had a fiancée said that they feared that participating
in the trial might disrupt existing close relationships.
Women feared that their intent to take part would signal
to their male partners that they have an HIV infection.
They said that these opinions could create conflicts with
their partners. Young men, in particular, expressed con-
cern about their intimate relationships:
The fiancée won't trust you from the moment you plan
to get the vaccine. She will think that by taking part
you are infected straight away ... She will believe that
you have been given the virus and so she will also be
infected (Young policeman 2, Group 4).
Another participant argued that problems with a fian-
cée arise only if she does not understand about the HIV
vaccine trial. He added:
I think there will be a problem with the fiancée
because I have one. Perhaps I will explain to her that I
have joined the HIV vaccine trial. If I will not explain
properly to make her understand, everything will be
interrupted... that will be the end of the relationship...
(Young policeman 9, Group 4).
Others in the group laughed and nodded as a sign of an
experience to identify with.
Existing social relationships and dependencies (parents
expecting the young people to support them in their old
age) were described as barriers to participating in the
trial. The participants said that parents have a strong
influence on the lives of young people. Young people saw
themselves as an asset for the future with responsibilities
towards their parents. These young people speculated
that parents would expect them not to take part in the
trial since they depend on each other. The parents were
said to worry that the vaccine could cause side effects:
Some of us are taken care of by our parents. Now what
would your father say if you get problems? They [par-
ents] will query: 'Don't you know that we depend on
you?' (Young policeman 6, Group 4).
The caregivers also experienced resistance from rela-
tives against their taking part in the vaccine trial. Their
relatives in some cases stated that taking part in the trial
would be like killing oneself. Participants suspected that
these relatives would warn them against enrolling in the
trial because of unknown side effects. The participants
became more worried when knowledgeable people cau-
tioned them. One participant shared:
Personally, I came across such a situation two months
after the seminar. I took my documents home [the HIV
vaccine trial education materials]. When my relatives
read those documents, they were the first ones to warn
me: 'Leave it [the trial], and leave it completely'. Many
of them, including a doctor from a cancer institute...
Now even a person with education became the first one
to oppose me. What about those with no education?
(Caregiver 1, Group 8).
Nevertheless, members of the caregiver group said that
some of their relatives would support participation in the
trial if they understood the importance of the vaccines.
They related this positive assumption based on the expe-
riences of people who take their children to receive avail-
able vaccines to prevent various diseases. Likewise, it is
possible that they could motivate others to participate in
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tion.
Reproduction and pregnancy norms
Participants voiced concern over restrictions imposed
while participating in the trial that would threaten the
desire to become pregnant. More often they were con-
cerned about the views of others on the effects of taking
part in the HIV vaccine trial on their reproductive ability.
Both men and women in the study expressed a fear of
postponing pregnancy and described how they had been
subject to negative views from others. Young unmarried
men without children expressed a loss of confidence in
the vaccine trial after recalling parents' warnings:
A parent can tell you that: 'If you are vaccinated and
get married you will not get children'. He or she thinks
if you get the vaccine you will not get a child... (Young
policeman 1, Group 4).
Another participant emphasised:
If you get vaccinated you will not get children when
you get married ... you will not get a child... (Young
policeman 5, Group 4).
Older policewomen also expressed concern over the
vaccine rules on pregnancy norms and the possible reac-
tions of sexual partners. These women feared that post-
poning pregnancy because of enrolment in the vaccine
trial could be a major concern to their husbands and boy-
friends:
The problem is with the family [husband], that is when
it becomes difficult. I get the vaccine and my husband
wants a child then ... I think problems will start there
(Older policewoman 1, Group 2).
Another group member stated:
There is a problem with girlfriend and boyfriend. For
example, with the boyfriend he could stay with a
woman for a long time, outside marriage lock and he
wants to have a child with her ... if she postpones, of
course the friendship will end (Older policewoman 4,
Group 2).
They also raised personal doubts about their reproduc-
tive capacity:
Is there any possibility for me to get a child? Won't they
[the researchers] just destroy my gametes! (Older
policewoman 3, Group 2).
Young women reasoned around the possibility of
becoming infertile after taking part in the trial:
There are some women without a child and other peo-
ple tell them that following vaccination they will never
conceive! (Young policewoman 7, Group 1).
In addition, the low ranking policemen expressed con-
cern over possible side effects of the vaccine on reproduc-
tive health, including foetal abnormalities and impotence
in men. They suspected that children might be born with
abnormalities because of drugs such as oral contracep-
tives. They reasoned that similar effects could arise from
the HIV vaccine. They also suspected the vaccine could
make men impotent:
People know exactly that children are being born with
abnormalities because of drugs [contraceptives]. And
now an HIV vaccine has arrived! (Low ranking police-
man 3, Group 6).
Another policeman added:
People are thinking a lot about this vaccine, some say
why should we be tested with this vaccine? Why not the
whole country? Another one says this will finish us,
another one that they [the researchers] want to make
us impotent ... (Low ranking policeman 5, Group 6).
Thus, fear among participants was connected with
reproduction and pregnancy issues.
Responsibility for others
Another factor for which participants felt responsible was
their families, particularly their children. They worried
that an experimental vaccine may have a negative out-
come, in the extreme case death, if the trial failed. Older
married men felt that they were consciously accepting the
possibility of death by taking part in the trial, and that this
may, in turn, affect the children's future. Although they
accepted that death is natural, they said they would prefer
a natural death:
Psychologically it will be bad. We know dying is
unavoidable but you can never go and stand on the
road and let the car knock you down and you die!
Nobody wants to die. All of us here [he pointed to oth-
ers in the group], we want to stay with our children
until they see the last tooth getting out... (Married
policeman 1, Group 7).
Lack of insurance was described as aggravating the
consequences of death that may result from taking part in
the trial. They requested that life insurance for their fam-
ilies be guaranteed following their decision to take part in
the trial:
Will I be insured if I die after introducing the virus?
What will I leave my children with? We have African
families ... One thinks that if I die after being vacci-
nated; won't I leave them [the family] in difficulties? I
better not go for vaccine to be implanted [with HIV in
my blood]... (Low ranking policewoman 1, Group 3).
Others in the group confirmed the possibility that peo-
ple would not dare to take part in the trial because of
uncertainties about their children's future in the event of
a vaccine-related death.
Uncertainty of risks and opportunities
Risks for HIV infection, myths about the vaccine's side effects
Participants expressed a fear of negative outcomes from
an experimental vaccine. They believed that the outcome
of the vaccination was uncertain. They expressed worries
that the trial would affect them in diverse ways. They
believed that the vaccine consisted of two shots, the first
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erase the HIV infection. The males shared:
I think one will not take part in the trial because in the
trial viruses must be introduced. If it is for HIV, you
are given that vaccine... (Young policeman 12, Group
4).
Another participant added:
How can you protect something [a healthy person]
without something [the existence of HIV]? I use a gate
because I know thieves might come inside to steal. So
how can you put a vaccine if you don't have HIV? The
main belief is that you cannot protect something that
does not exist (Young policeman 5, Group 4).
The participants believed that HIV could be transmit-
ted through either the vaccine or unsafe sex. They rea-
soned that getting HIV through the vaccine involves pain;
while with unsafe sex it involves pleasure. Married police-
men explained why a fear of HIV transmission by unsafe
sex should differ from that of the vaccine. One partici-
pant commented:
There [in sexual intercourse] you enjoy. That is what it
means. It is not like when you are being vaccinated.
There [sex] you know you are straightforward enjoying.
So it is right if I get infected (Married policeman 7,
Group 7).
Another participant added another aspect of infection
through sex:
You know with sex, it is imaginary. One goes thinking
that he is safe and may be also my partner is safe. You
see when doing sex, one does not know... That is the
way it is, but sex and vaccine differ a little bit (Mar-
ried policeman 2, Group 7).
Another fear arose from the belief that participating in
the trial would introduce the HIV to participants, who
would in turn infect their spouses.
In other groups, participants had different views on
how vaccines work. They perceived that an HIV vaccine
might contain the live virus, which could cause HIV
infection, and wondered about how the same vaccine
could provide protection. They shared their perception in
the following way:
Most people say you will be given the HIV vaccine first,
and then you get the medicines. Others said after being
vaccinated you will be told to go and engage in sex to
see if you will get HIV infection or not... (Young police-
woman 6, Group 1).
Others expressed a fear of seeing a needle with vaccine
directed towards the skin as an indication of both physi-
cal harm and the possibility of death. One participant
pointed with emotion at his upper arm muscle where the
vaccine would be injected, believing that it signalled
death or survival as the only possible outcomes to expect
from the moment the vaccine is injected. He stated:
When they do it on me pa-a-p [he was pointing at the
vaccination site on his upper arm] ... one leg is in [life]
and another is out [death] and this makes people
worry so much (High ranking policeman 5, Group 5).
Thus, they reasoned that multiple risks could affect
their decision about taking part in the HIV vaccine trial.
Such worries were fuelled by inadequate knowledge and
myths about the vaccine.
Time of knowing HIV status
The time of knowing whether one is HIV infected or not
was also discussed. The follow-ups and routine HIV-test-
ing associated with participating in the trial will provide
early knowledge about whether one is infected, sooner
than would be the case if infected through unsafe sex.
They viewed the revelation of their status too early as a
problem, and therefore people are more afraid of the HIV
vaccine than they are of AIDS. One participant remarked:
Do you know why people are more afraid of the vac-
cine than AIDS itself? They will become aware earlier
[that they are HIV positive]! When she or he comes for
testing, she or he will know that he or she is infected.
All these will be because of vaccine. Second, is the
belief that once I go to get the vaccine I will be counted
among the infected. So, fear is fixed in the heart that,
what if I die? I have the virus introduced in the body. ...
It is better you look for it [HIV through unsafe sex]
yourself rather than being implanted (Low ranking
policewoman 11, Group 3).
The caregiver group had more positive views towards
the vaccine trial than the other groups. Their experience
had convinced them that it is not possible to be infected
with HIV through this vaccine. They did, however,
express concern about coping with results from any
health test, which is discussed in the following section.
Medical check ups: fear versus opportunities
The participants expressed another fear arising from the
thorough medical check ups that were a condition for
inclusion in the trial. These check ups might reveal that
they were infected with HIV or had other life-threatening
diseases. A participant expressed:
You [the researchers] are saying one should undergo
testing of everything in the body to see what problems
are there. One could have life-threatening condition.
Now when he or she is told by another person that he
has an untreatable disease, that person will start
weakening slowly. Some people can go for testing but
cannot take results. I think testing is an issue! (Care-
giver 6, Group 8).
Others, on the other hand, saw this complete medical
check up as an opportunity for receiving free medical ser-
vices for the diseases that may be discovered:
Surely, I will be motivated as I think the big issue is to
be checked. It's useful for me since if I am found with
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ful since I will be given immunity [treatment] (High
ranking policeman 7, Group 5).
This issue of free medical care as a benefit was dis-
cussed in other groups:
This check up can reveal some diseases that will be
treated at the researchers' cost. This is a big advan-
tage, to be treated free and know your status [health
status] (Young policeman 2, Group 4).
Another participant insisted:
I think the big issue here is that motivation of health
services. The big motivation is to get free medical ser-
vices for the participant ... (Low ranking policeman 3,
Group 6).
Researchers' assurance and mistrust
Participants expressed trust over what they regarded as
the explanations by the skilled researchers about the ben-
efits of vaccine trial and therefore they positioned them-
selves as recipients. One caregiver said:
I think the one who can influence is you [the modera-
tor or researchers], with the knowledge you have or the
one who gave you education. It is a person with this
knowledge who can influence you (Caregiver 2, Group
8).
Participants reasoned that the police force may have
been selected for the vaccine trial because of the large
number of police officers lost through AIDS. Some par-
ticipants, however, expressed the suspicion that the
researchers intended to implant viruses in them instead
of preventing the infection. They speculated that the
researchers were hiding the truth about the effects of the
vaccine:
They [researchers] are liars. They will plant virus on
us! ...Why don't they try with animals? (Low ranking
policewoman 12, Group 3).
This mistrust seemed to arise from the fact that the
vaccine was imported to the country. The participants
reasoned that if such a vaccine had been proved safe after
testing in animals and then used on human beings else-
where, there was no need to test it again on Tanzanian
police officers. They argued that the researchers in the
vaccine project might benefit financially from the trial:
They [the researchers] already got money from there
[donors]. Now to prove they have done the job they are
moving around here... A neighbour told me not to
engage in the trial (Low ranking policeman 1, Group
6).
In summary, participants expressed doubts and fear
concerning taking part largely because of inadequate
understanding of the Phase I or II HIV vaccine trial. Nev-
ertheless, they saw that the trial offered certain opportu-
nities.
Discussion
We describe here the reasons that participants are inter-
ested in taking part in an HIV vaccine trial. Their interest
is tempered by perceived threats that they fear may inter-
fere with their normal lives. They express concern over
the possible loss of close relationships and interference
with pregnancy norms. They are concerned with the risk
of acquiring HIV infection through the vaccine, the time
of knowing whether they are infected or not through rou-
tine testing, and the implications of undergoing complete
medical check ups. The researchers conducting the trial
are seen by some as trustworthy and by others as suspi-
cious.
The concern expressed over the possible loss of close
relationships is associated with the roles of significant
others such as parents, sexual partners, relatives, friends
and colleagues. Young participants felt threatened by
negative opinions from their significant others more
often than older participants, implying that these bonds
are crucial in young people's lives. Since this is the age
group that has been targeted for Phase I and II HIV vac-
cine trials, the views and influence of significant others
pose an important challenge. Those carrying out trials
need to be aware of these concerns, and they need to be
aware of the presence of significant others and their influ-
ence in a decision whether to participate in the vaccine
trial. Previous studies have shown that significant others
form an important incentive during participation in an
HIV vaccine trial [22,29]. Significant others may exert a
powerful influence on a decision to engage in a scientific
investigation. Significant others are mentioned as both
motivators for, and barriers to, trial participation in a
study of community members in South Africa [5]. Thus,
significant others can contribute to success or failure in
recruiting participants in an HIV vaccine trial. It may be
important to involve those who form 'close relationships
with the targeted volunteers' from the onset when design-
ing HIV vaccine trials, and encouraging them to share
their concerns directly with the trial team.
Pregnancy restriction is mentioned often, suggesting
that recruitment of volunteers in the reproductive age
group will be a challenge, because of the fear of interfer-
ence with their reproductive capacities and pregnancy
norms. One of the criteria for inclusion in the HIV vac-
cine trial is an age limit that focuses on young people who
expect to have children in the future. Both men and
women often voice issues relating to pregnancy restric-
tion. This may be due to the experience of child nurtur-
ing, and it may be due to the values placed on children in
Tanzania and African contexts [30,31]. Although the
pregnancy restriction during the trial is temporary, the
participants expressed fear that the vaccine would irre-
versibly affect their childbearing ability. These concerns
have been expressed in other populations [13,14], show-
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cine trial participation in different contexts. More
knowledge must be provided to reassure the participants
about the trial safety.
The reasoning that participation in an HIV vaccine trial
involves implantation of viruses in one's body fuels fear,
and participants expressed a worry about getting an HIV
infection from a deliberate decision. This fear, however,
arises from inadequate understanding and limited infor-
mation about the contents of the vaccine and how it
works. It is generally believed that giving public health
information changes knowledge, but we did not assess
the extent of knowledge change before and after the
workshop to find out whether the information provided
had been correctly received. Lack of information about
HIV vaccines and confusion about how vaccines work
has been noted in another study [32]. Similarly, a study in
Uganda reported fears about deliberate infection with
HIV from participation in a trial [12]. Other studies have
also reported a fear of vaccine-induced HIV infection
[4,6,14,16,33] and a fear of detrimental effects on partici-
pants' lives [34,35].
The discovery of one's HIV status as a consequence of
the routine testing in the trial aroused fear. However,
approaches to HIV prevention in Tanzania have sug-
gested that knowledge of one's HIV status can empower
individuals to take precautions to protect against either
acquiring or transmitting the disease [36]. Similarly, if
many people prefer to remain ignorant of their HIV sta-
tus as long as possible following accidental exposure to
infection, this will undermine government efforts to pre-
vent new infections. It is important to stress the impor-
tance of early HIV testing and to promote safe sex during
the recruitment of volunteers to future HIV vaccine tri-
als.
Complete medical check ups that follow from partici-
pation in the trial provide the opportunity of free health-
care, but this is tempered by the fear of discovering that
one is suffering from an unknown disease. The threat of
finding out that one is suffering from a life-threatening
disease may give rise to a feeling of panic, a feeling that
one is facing death too early. The worry experienced by
participants is exacerbated by the lack of adequate insur-
ance in Tanzania and the expected payout from the insur-
ance scheme. Similarly, compensation for families in the
event of a poor trial outcome is considered important in
south India [37]. Among parents in Gambia, a decision to
let their children participate in a trial involved a sense of
balance between the benefit of free medical treatment
and the danger of one's child being drained of blood [17].
Getting free healthcare in a trial appears to be important
for the willingness of adolescents to take part [38]. Partic-
ipants must weigh the benefits against the risks of partici-
pating in a trial. It is, therefore, important that the
consequences of taking part in a trial are transparent.
Mistrust of the researchers adds challenges to scientific
investigations. Doubt about the integrity of researchers
can seriously interfere with recruitment, not only to an
HIV vaccine trial but also to future trials with other prod-
ucts that are not related to an HIV vaccine. Other studies
have revealed mistrust of scientists conducting trials
[8,14,39-41]. Trust for researchers is related to the ques-
tion of how donor funds are used, and this is not surpris-
ing. AIDS-related funding for low-income countries such
as Tanzania is provided by the international community
(donors) [42], and usually reaches the projects that spend
it via one (or more) of four main funding streams: dona-
tions from national governments; multilateral funding
organisations; the private sector; and domestic spending.
Mismanagement may not be so much a case of corrup-
tion, but rather that money is simply not being spent
wisely, or used to its maximum effect. A government
department, for example, may spend excessive amounts
on paying for experts to travel to projects and stay in
expensive accommodation, when the money could be
better spent carrying out work on the ground. Such phe-
nomena may lead people to believe that the researchers
are benefiting from AIDS-related funding. Hence, the
concerns raised by our participants (which may be shared
by the whole nation, not only the participants) are legiti-
mate and need attention. Conversely, participation in the
trial is viewed as an important step in helping researchers
to find an effective HIV vaccine [34].
We cannot generalize the results presented here to
other populations, but the qualitative approach we have
used has enabled us to determine the reasons behind the
participants' decision whether to take part in an HIV vac-
cine trial. Focus group discussions (FGDs) were useful in
helping participants to explore and clarify their views in
ways that would be less accessible in a one-to-one inter-
view. Participants were able to explore issues that were
important to them in their own vocabulary as shown in
the quotes. (It is possible that one-to-one interviews are
useful in providing an in-depth description of some state-
ments). The use of FGDs shaped the data by generating a
shared perspective. Group interaction encouraged partic-
ipants to mention sensitive issues and issues that
researchers had not thought about. The use of FGDs
obtains data more rapidly than one-to-one interviews and
it is thus cheaper [43]. In addition, the use of an approach
using interpretive descriptions (ID) can guide study
design. It assisted in generating practice-relevant data
and examining the responses of the participants with the
goal of identifying themes and patterns, and accounting
for variations between groups. ID is a relatively new qual-
itative method in health care [44], that requires the user
to interpret their findings carefully, in order to retain the
original meaning of the participants' perspectives.
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The opinions and reasons for deciding whether to take
part in an HIV vaccine trial among police officers are
important. These findings have immediate implications
for how Phase I and II HIV vaccine trials among police
officers in Dar es Salaam, Tanzania are designed. The use
of the qualitative research method described here
enabled us to elicit the perceptions and understanding of
HIV vaccine trials in a local context from potential volun-
teers. The results can be used when modifying the trial
recruitment materials to ensure that potential volunteers
and the general population are given correct information
before Phase I and II HIV vaccine trials are implemented.
In particular, the role of significant others and a mistrust
of researchers and vaccine products are important issues
to address when designing future trials. These issues
should be addressed from the onset of trial design and
monitored throughout the trials because they may also
influence whether those who volunteer for trials com-
plete the trial. Fear of vaccine side effects requires that
potential volunteers be given extensive knowledge and
reassurance, to ensure that they adequately understand
the trial and to increase the probability that those who
volunteer complete the trial. Further studies are planned
that will follow up these results and examine their signifi-
cance for policy formulation when conducting trials with
different groups in similar settings.
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